Literature DB >> 25559817

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

Nadine M Tung1, Eric P Winer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25559817     DOI： 10.1200/JCO.2014.59.6031

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

Review 2.  Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.

Authors:  Juan Jin; Wenwen Zhang; Wenfei Ji; Fang Yang; Xiaoxiang Guan
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

3.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Authors:  Carsten Denkert; Stephan Wienert; Audrey Poterie; Sibylle Loibl; Jan Budczies; Sunil Badve; Zsuzsanna Bago-Horvath; Anita Bane; Shahinaz Bedri; Jane Brock; Ewa Chmielik; Matthias Christgen; Cecile Colpaert; Sandra Demaria; Gert Van den Eynden; Giuseppe Floris; Stephen B Fox; Dongxia Gao; Barbara Ingold Heppner; S Rim Kim; Zuzana Kos; Hans H Kreipe; Sunil R Lakhani; Frederique Penault-Llorca; Giancarlo Pruneri; Nina Radosevic-Robin; David L Rimm; Stuart J Schnitt; Bruno V Sinn; Peter Sinn; Nicolas Sirtaine; Sandra A O'Toole; Giuseppe Viale; Koen Van de Vijver; Roland de Wind; Gunter von Minckwitz; Frederick Klauschen; Michael Untch; Peter A Fasching; Toralf Reimer; Karen Willard-Gallo; Stefan Michiels; Sherene Loi; Roberto Salgado
Journal:  Mod Pathol       Date:  2016-07-01       Impact factor: 7.842

4.  Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.

Authors:  Evan C Lien; Costas A Lyssiotis; Ashish Juvekar; Hai Hu; John M Asara; Lewis C Cantley; Alex Toker
Journal:  Nat Cell Biol       Date:  2016-04-18       Impact factor: 28.824

Review 5.  Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.

Authors:  Paula García-Teijido; María Luque Cabal; Ignacio Peláez Fernández; Yolanda Fernández Pérez
Journal:  Clin Med Insights Oncol       Date:  2016-04-05

Review 6.  Novel therapeutic strategies for patients with triple-negative breast cancer.

Authors:  Jun-Fei Zhang; Jia Liu; Yu Wang; Bin Zhang
Journal:  Onco Targets Ther       Date:  2016-10-21       Impact factor: 4.147

7.  An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Authors:  Giulia Bottai; Carlotta Raschioni; Agnese Losurdo; Luca Di Tommaso; Corrado Tinterri; Rosalba Torrisi; Jorge S Reis-Filho; Massimo Roncalli; Christos Sotiriou; Armando Santoro; Alberto Mantovani; Sherene Loi; Libero Santarpia
Journal:  Breast Cancer Res       Date:  2016-12-03       Impact factor: 6.466

Review 8.  Role of Platinum in Early-Stage Triple-Negative Breast Cancer.

Authors:  Alyssa La Belle; Jude Khatib; William P Schiemann; Shaveta Vinayak
Journal:  Curr Treat Options Oncol       Date:  2017-11-06

9.  Triple-negative breast cancer: treatment challenges and solutions.

Authors:  Joëlle Collignon; Laurence Lousberg; Hélène Schroeder; Guy Jerusalem
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-05-20

10.  Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.

Authors:  Shinjiro Sakamoto; Satoko Matsueda; Shinzo Takamori; Uhi Toh; Masanori Noguchi; Shigeru Yutani; Akira Yamada; Shigeki Shichijo; Teppei Yamada; Shigetaka Suekane; Kouichiro Kawano; Tetsuro Sasada; Noboru Hattori; Nobuoki Kohno; Kyogo Itoh
Journal:  Cancer Sci       Date:  2015-09-25       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.